title: Photodynamic therapy in gynaecologic cancer.
abstract: We started photodynamic therapy in gynaecologic tumors in 1988. Seven patients with endometrial carcinomas stage FIGO 1a (restricted to the endometrium) were treated primarily and also 4 patients with recurrences of vaginal and vault cervix carcinoma, carcinoma of the corpus uteri and the vulva. Residual tumors after conventional therapy of cervix and vulvar carcinoma were treated in 2 patients. Tumor illumination was performed by an Argon dye laser 24-72 h following the intravenous administration of haematoporphyrin derivatives (HPD) (Photosan III, 2 mg kg-1 body weight). The intracavitary tumor irradiation by means of a glass fibre was controlled by ultrasound. Superficial and small lesions of vaginal and vulvar carcinomas were subjected to superficial light irradiation; whereas tumors exceeding 1 cm in depth were treated interstitially. Tumor response was estimated 1 month after therapy. Complete remission was achieved in 8 patients, partial remission in 2, and no remission in 3 cases. Subsequent radiotherapy was performed in 3 patients with bleeding endometrial cancer with consecutive complete response.
authors.affiliation: Special Department of Radiotherapy, City Hospital, Lainz, Austria.
authors.forename: H
authors.initials: H
authors.lastname: Koren
authors.forename: G
authors.initials: G
authors.lastname: Alth
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006415:Hematoporphyrins; D006801:Humans; D007834:Lasers; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D014594:Uterine Neoplasms / Q000188:drug therapy; D014625:Vaginal Neoplasms / Q000188:drug therapy; D014846:Vulvar Neoplasms / Q000188:drug therapy
chemical_list: D006415:Hematoporphyrins; D017319:Photosensitizing Agents; C071875:photosan III